Does the media favor ELDN or CLNN?

In the previous week, Eledon Pharmaceuticals had 3 more articles in the media than Clene. MarketBeat recorded 4 mentions for Eledon Pharmaceuticals and 1 mentions for Clene. Eledon Pharmaceuticals' average media sentiment score of 0.90 beat Clene's score of 0.00 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eledon Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Clene 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, ALXO or CLNN?

Clene has higher revenue and earnings than ALX Oncology. Clene is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALX Oncology N/A N/A -$101.69M -$1.49 N/A Clene $200K 337.39 -$26.17M -$3.20 N/A

Is ALXO or CLNN more profitable?

ALX Oncology has a net margin of 0.00% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets ALX Oncology N/A -124.06% -85.57% Clene -25,009.70% N/A -137.98%

Does the media favor ALXO or CLNN?

In the previous week, ALX Oncology had 1 more articles in the media than Clene. MarketBeat recorded 2 mentions for ALX Oncology and 1 mentions for Clene. ALX Oncology's average media sentiment score of 1.31 beat Clene's score of 0.00 indicating that ALX Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALX Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Clene 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ZSQR or CLNN?

Clene has a consensus target price of $33.25, suggesting a potential upside of 529.73%. Given Clene's stronger consensus rating and higher possible upside, analysts plainly believe Clene is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Clene 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Does the media favor ZSQR or CLNN?

In the previous week, Coeptis Therapeutics and Coeptis Therapeutics both had 1 articles in the media. Coeptis Therapeutics' average media sentiment score of 0.97 beat Clene's score of 0.00 indicating that Coeptis Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coeptis Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Clene 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BCYC or CLNN?

In the previous week, Bicycle Therapeutics had 7 more articles in the media than Clene. MarketBeat recorded 8 mentions for Bicycle Therapeutics and 1 mentions for Clene. Clene's average media sentiment score of 0.00 beat Bicycle Therapeutics' score of -0.27 indicating that Clene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicycle Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Clene 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate CLNN or TKNO?

Clene currently has a consensus target price of $33.25, suggesting a potential upside of 529.73%. Given Clene's stronger consensus rating and higher possible upside, equities research analysts clearly believe Clene is more favorable than Alpha Teknova. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Clene 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 Alpha Teknova 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings and valuation, CLNN or TKNO?

Alpha Teknova has higher revenue and earnings than Clene. Alpha Teknova is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Clene $200K 337.39 -$26.17M -$3.20 N/A Alpha Teknova $40.52M 7.30 -$17.26M -$0.32 N/A

Is CLNN or TKNO more profitable?

Alpha Teknova has a net margin of -41.07% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat Alpha Teknova's return on equity. Company Net Margins Return on Equity Return on Assets Clene -25,009.70% N/A -137.98% Alpha Teknova -41.07% -24.32% -16.34%

Does the media prefer CLNN or TKNO?

In the previous week, Clene and Clene both had 1 articles in the media. Clene's average media sentiment score of 0.00 equaled Alpha Teknova'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Clene 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alpha Teknova 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Clene (CLNN) Competitors

$5.28 +0.09 (+1.73%)

Closing price 08/4/2026 04:00 PM Eastern

Extended Trading

$5.40 +0.12 (+2.25%)

As of 07:52 AM Eastern

Compare

CLNN vs. ELDN, ALXO, ZSQR, BCYC, and TKNO

Should you buy Clene stock or one of its competitors? MarketBeat compares Clene with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Clene include Eledon Pharmaceuticals (ELDN), ALX Oncology (ALXO), Coeptis Therapeutics (ZSQR), Bicycle Therapeutics (BCYC), and Alpha Teknova (TKNO).

How does Clene compare to Eledon Pharmaceuticals?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Clene (NASDAQ:CLNN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. Comparatively, 23.3% of Clene shares are owned by institutional investors. 9.6% of Eledon Pharmaceuticals shares are owned by company insiders. Comparatively, 28.3% of Clene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Eledon Pharmaceuticals has a net margin of 0.00% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%
Clene	-25,009.70%	N/A	-137.98%

Eledon Pharmaceuticals has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market. Comparatively, Clene has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market.

In the previous week, Eledon Pharmaceuticals had 3 more articles in the media than Clene. MarketBeat recorded 4 mentions for Eledon Pharmaceuticals and 1 mentions for Clene. Eledon Pharmaceuticals' average media sentiment score of 0.90 beat Clene's score of 0.00 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eledon Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Clene	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Eledon Pharmaceuticals currently has a consensus target price of $9.67, suggesting a potential upside of 176.98%. Clene has a consensus target price of $33.25, suggesting a potential upside of 529.73%. Given Clene's stronger consensus rating and higher possible upside, analysts plainly believe Clene is more favorable than Eledon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Clene has higher revenue and earnings than Eledon Pharmaceuticals. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A
Clene	$200K	337.39	-$26.17M	-$3.20	N/A

Summary

Clene beats Eledon Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Clene compare to ALX Oncology?

ALX Oncology (NASDAQ:ALXO) and Clene (NASDAQ:CLNN) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.

In the previous week, ALX Oncology had 1 more articles in the media than Clene. MarketBeat recorded 2 mentions for ALX Oncology and 1 mentions for Clene. ALX Oncology's average media sentiment score of 1.31 beat Clene's score of 0.00 indicating that ALX Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALX Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Clene	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Clene has higher revenue and earnings than ALX Oncology. Clene is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A
Clene	$200K	337.39	-$26.17M	-$3.20	N/A

ALX Oncology has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market. Comparatively, Clene has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market.

98.0% of ALX Oncology shares are owned by institutional investors. Comparatively, 23.3% of Clene shares are owned by institutional investors. 12.4% of ALX Oncology shares are owned by insiders. Comparatively, 28.3% of Clene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

ALX Oncology has a net margin of 0.00% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-124.06%	-85.57%
Clene	-25,009.70%	N/A	-137.98%

ALX Oncology presently has a consensus price target of $4.60, suggesting a potential upside of 133.50%. Clene has a consensus price target of $33.25, suggesting a potential upside of 529.73%. Given Clene's stronger consensus rating and higher probable upside, analysts plainly believe Clene is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Clene beats ALX Oncology on 8 of the 15 factors compared between the two stocks.

How does Clene compare to Coeptis Therapeutics?

Coeptis Therapeutics (NASDAQ:ZSQR) and Clene (NASDAQ:CLNN) are related small-cap companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk.

Clene has a consensus target price of $33.25, suggesting a potential upside of 529.73%. Given Clene's stronger consensus rating and higher possible upside, analysts plainly believe Clene is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Coeptis Therapeutics has a beta of -0.19, suggesting that its share price is 119% less volatile than the broader market. Comparatively, Clene has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

Coeptis Therapeutics has a net margin of -810.04% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%
Clene	-25,009.70%	N/A	-137.98%

13.9% of Coeptis Therapeutics shares are held by institutional investors. Comparatively, 23.3% of Clene shares are held by institutional investors. 24.3% of Coeptis Therapeutics shares are held by company insiders. Comparatively, 28.3% of Clene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Coeptis Therapeutics and Coeptis Therapeutics both had 1 articles in the media. Coeptis Therapeutics' average media sentiment score of 0.97 beat Clene's score of 0.00 indicating that Coeptis Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coeptis Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Clene	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Coeptis Therapeutics has higher earnings, but lower revenue than Clene. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coeptis Therapeutics	N/A	N/A	-$11.92M	-$2.52	N/A
Clene	$200K	337.39	-$26.17M	-$3.20	N/A

Summary

Clene beats Coeptis Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Clene compare to Bicycle Therapeutics?

Bicycle Therapeutics (NASDAQ:BCYC) and Clene (NASDAQ:CLNN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.

In the previous week, Bicycle Therapeutics had 7 more articles in the media than Clene. MarketBeat recorded 8 mentions for Bicycle Therapeutics and 1 mentions for Clene. Clene's average media sentiment score of 0.00 beat Bicycle Therapeutics' score of -0.27 indicating that Clene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicycle Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Clene	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bicycle Therapeutics has a beta of 1.55, meaning that its share price is 55% more volatile than the broader market. Comparatively, Clene has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market.

Bicycle Therapeutics presently has a consensus target price of $13.86, indicating a potential upside of 251.70%. Clene has a consensus target price of $33.25, indicating a potential upside of 529.73%. Given Clene's stronger consensus rating and higher probable upside, analysts plainly believe Clene is more favorable than Bicycle Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Clene has lower revenue, but higher earnings than Bicycle Therapeutics. Clene is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$72.86M	3.78	-$218.96M	-$2.73	N/A
Clene	$200K	337.39	-$26.17M	-$3.20	N/A

86.2% of Bicycle Therapeutics shares are owned by institutional investors. Comparatively, 23.3% of Clene shares are owned by institutional investors. 22.0% of Bicycle Therapeutics shares are owned by insiders. Comparatively, 28.3% of Clene shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Bicycle Therapeutics has a net margin of -311.11% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat Bicycle Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-311.11%	-33.22%	-27.79%
Clene	-25,009.70%	N/A	-137.98%

Summary

Bicycle Therapeutics and Clene tied by winning 8 of the 16 factors compared between the two stocks.

How does Clene compare to Alpha Teknova?

Clene (NASDAQ:CLNN) and Alpha Teknova (NASDAQ:TKNO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

Clene has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, Alpha Teknova has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market.

23.3% of Clene shares are owned by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are owned by institutional investors. 28.3% of Clene shares are owned by company insiders. Comparatively, 13.2% of Alpha Teknova shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Clene currently has a consensus target price of $33.25, suggesting a potential upside of 529.73%. Given Clene's stronger consensus rating and higher possible upside, equities research analysts clearly believe Clene is more favorable than Alpha Teknova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Alpha Teknova has a net margin of -41.07% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat Alpha Teknova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Clene	-25,009.70%	N/A	-137.98%
Alpha Teknova	-41.07%	-24.32%	-16.34%

Alpha Teknova has higher revenue and earnings than Clene. Alpha Teknova is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clene	$200K	337.39	-$26.17M	-$3.20	N/A
Alpha Teknova	$40.52M	7.30	-$17.26M	-$0.32	N/A

In the previous week, Clene and Clene both had 1 articles in the media. Clene's average media sentiment score of 0.00 equaled Alpha Teknova'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Clene	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alpha Teknova	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Clene beats Alpha Teknova on 9 of the 14 factors compared between the two stocks.

Get Clene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLNN vs. The Competition

Export

Metric	Clene	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$66.32M	$11.49B	$6.83B	$12.77B
Dividend Yield	N/A	2.73%	2.60%	10.01%
P/E Ratio	-1.65	791.61	279.15	25.53
Price / Sales	337.39	733.37	587.36	92.31
Price / Cash	N/A	71.54	72.11	49.39
Price / Book	-3.26	10.85	13.06	6.11
Net Income	-$26.17M	$2.81B	$3.48B	$347.58M
7 Day Performance	11.86%	2.66%	3.38%	4.91%
1 Month Performance	-13.44%	-3.16%	-2.81%	-2.06%
1 Year Performance	43.09%	190.97%	73.07%	21.03%

Clene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLNN Clene	2.0758 of 5 stars	$5.28 +1.7%	$33.25 +529.7%	+41.2%	$66.32M	$200K	N/A	100	Gap Up
ELDN Eledon Pharmaceuticals	2.8697 of 5 stars	$3.57 -0.3%	$9.67 +170.8%	+7.4%	$275.56M	N/A	N/A	10
ALXO ALX Oncology	2.2267 of 5 stars	$2.02 -0.5%	$4.60 +127.7%	+235.8%	$273.16M	N/A	N/A	40	Positive News Upcoming Earnings
ZSQR Coeptis Therapeutics	0.1547 of 5 stars	$4.81 -8.6%	N/A	-62.8%	$270.53M	$1.36M	N/A	2
BCYC Bicycle Therapeutics	2.8462 of 5 stars	$3.95 +2.1%	$14.00 +254.4%	-51.1%	$270.17M	$63.50M	N/A	240	Positive News Earnings Report Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLNN) was last updated on 8/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Clene (CLNN) Competitors

CLNN vs. ELDN, ALXO, ZSQR, BCYC, and TKNO

How does Clene compare to Eledon Pharmaceuticals?

Summary

How does Clene compare to ALX Oncology?

Summary

How does Clene compare to Coeptis Therapeutics?

Summary

How does Clene compare to Bicycle Therapeutics?

Summary

How does Clene compare to Alpha Teknova?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLNN vs. The Competition

Clene Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Clene (CLNN) Competitors

CLNN vs. ELDN, ALXO, ZSQR, BCYC, and TKNO

How does Clene compare to Eledon Pharmaceuticals?

Do institutionals and insiders hold more shares of ELDN or CLNN?

Is ELDN or CLNN more profitable?

Which has more volatility & risk, ELDN or CLNN?

Does the media favor ELDN or CLNN?

Do analysts rate ELDN or CLNN?

Which has preferable valuation & earnings, ELDN or CLNN?

Summary

How does Clene compare to ALX Oncology?

Does the media favor ALXO or CLNN?

Which has stronger earnings and valuation, ALXO or CLNN?

Which has more volatility and risk, ALXO or CLNN?

Do institutionals & insiders hold more shares of ALXO or CLNN?

Is ALXO or CLNN more profitable?

Do analysts recommend ALXO or CLNN?

Summary

How does Clene compare to Coeptis Therapeutics?

Do analysts prefer ZSQR or CLNN?

Which has more risk and volatility, ZSQR or CLNN?

Is ZSQR or CLNN more profitable?

Do insiders & institutionals have more ownership in ZSQR or CLNN?

Does the media favor ZSQR or CLNN?

Which has stronger valuation & earnings, ZSQR or CLNN?

Summary

How does Clene compare to Bicycle Therapeutics?

Does the media favor BCYC or CLNN?

Which has more volatility and risk, BCYC or CLNN?

Do analysts prefer BCYC or CLNN?

Which has better valuation and earnings, BCYC or CLNN?

Do institutionals and insiders believe in BCYC or CLNN?

Is BCYC or CLNN more profitable?

Summary

How does Clene compare to Alpha Teknova?

Which has more volatility & risk, CLNN or TKNO?

Do insiders & institutionals have more ownership in CLNN or TKNO?

Do analysts rate CLNN or TKNO?

Is CLNN or TKNO more profitable?

Which has better earnings and valuation, CLNN or TKNO?

Does the media prefer CLNN or TKNO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLNN vs. The Competition

Clene Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools